Quality investors seeking companies that can be held for the long term are often on the hunt for businesses with durable competitive advantages, strong profitability, and solid financial health. The "Caviar Cruise" stock screener, inspired by the quality investing methodology outlined in Luc Kroeze's De Kaviaarformule, is one tool designed to surface such candidates. This screen applies a rigorous set of fundamental filters, focusing on consistent revenue and profit growth, high returns on invested capital, manageable debt, and high profit quality, to identify companies that exhibit the hallmarks of a quality business. When we ran this screen, Globus Medical Inc - A (NYSE:GMED) emerged as a compelling prospect worthy of a closer look.

Why Globus Medical Passes the Caviar Cruise Screen

The fundamental premise of the Caviar Cruise screen is to find companies that not only grow but do so efficiently and with improving profitability. Globus Medical checks the key boxes across several core criteria.

1. Revenue and Profit Growth with Improving Efficiency

The screen requires both revenue and EBIT (earnings before interest and taxes) to have grown at a compound annual growth rate (CAGR) of at least 5% over the past five years. More importantly, it demands that EBIT growth outpaces revenue growth, signaling improving operational efficiency and pricing power.

• Revenue Growth (5Y CAGR): 7.38% – comfortably above the 5% threshold.
• EBIT Growth (5Y CAGR): 36.04% – significantly outpacing revenue growth, which strongly suggests the company is becoming more profitable as it scales, just as the quality investing methodology prescribes.

2. Superior Return on Invested Capital (ROIC)

A central pillar of quality investing is the Return on Invested Capital (ROIC), which measures how effectively a company turns its invested capital into profit. The Caviar Cruise screen uses a strict variant, ROIC excluding cash, goodwill, and intangibles (ROICexgc) , with a minimum hurdle of 15%.

• ROICexgc: 24.17% – This is a standout figure. It indicates that for every dollar of core capital invested, Globus Medical generates nearly 25 cents in return. This level of ROIC not only clears the screen’s hurdle but also points to a strong competitive moat and efficient management.

3. Rock-Solid Financial Health

A quality company should not be burdened by excessive debt. The screen uses the Debt-to-Free Cash Flow (FCF) ratio to measure how many years it would take to pay off all debt using current free cash flow. A ratio under 5 is considered healthy.

• Debt / FCF Ratio: 0.00 – This is a near-perfect score, indicating the company has virtually no net debt. It is an exceptionally strong sign of financial stability, meaning the business is not reliant on borrowing to fuel its growth.

4. High Profit Quality

The profit quality metric (Free Cash Flow to Net Income ratio) checks how much of a company’s reported net profit is actually converted into hard cash. The screen looks for a 5-year average of at least 75%.

• Profit Quality (5y Average): 167.52% – Not only does this clear the 75% hurdle, but it exceeds 100% significantly. This suggests that the company’s free cash flow generation is even stronger than its net income, largely due to efficient capital management and healthy cash conversion. This is a hallmark of a mature, cash-generative business that can reward shareholders.

High-Level Fundamental Report Summary

Complementing the screen results, our detailed fundamental analysis report assigns Globus Medical a strong overall rating of 7 out of 10. The report highlights several key strengths:

• Profitability (Score: 8/10): The company demonstrates excellent return ratios (ROA, ROE, ROIC) and strong margins (profit, operating, gross), all ranking among the best in its industry. Margins have also been improving over the last few years.
• Health (Score: 8/10): Financially, Globus Medical is in outstanding shape. It boasts a pristine Altman-Z score of 10.83 (indicating negligible bankruptcy risk), a near-zero debt-to-FCF ratio, and strong liquidity ratios.
• Valuation (Score: 7/10): Despite being a high-quality company, the valuation remains attractive. Its P/E ratio of 17.84 is cheaper than about 82% of its industry peers, and its PEG ratio, which accounts for future growth, also suggests a reasonable price for the quality on offer.
• Growth (Score: 7/10): The company has a strong track record, with EPS growing 22.84% annually over the past five years. While future growth rates are expected to decelerate slightly, analysts still project average EPS growth of 11.57% in the coming years.

Analyst Views & Market Context

With the broader S&P 500 maintaining a positive trend in both the long and short term, quality growth stocks like Globus Medical are often in a favorable position. Analysts generally view the company as a well-managed player in the musculoskeletal and enabling technologies space, benefiting from long-term demographic trends in spine and orthopedic procedures. The attractive valuation relative to its quality and growth profile makes it a frequent topic of discussion among value-conscious growth investors.

Discover More Quality Candidates

Globus Medical is just one example of a company that meets the strict criteria of the Caviar Cruise screen. If you are interested in exploring a full list of stocks that pass this quality-oriented methodology, you can access the complete screen results and perform your own analysis.

[Click here to see the full Caviar Cruise screening results](https://www.chartmill.com/stock/stock-screener?sid=673&f=sl_rev5y_5_X,sl_roicNg_15_X,sl_debt2fcf_X_5,sl_profitQ5y_75_X,sl_ebit5yGrowth_5_X,exch_us&v=22&s=ta&sd=DESC&cpl=2&bc=false&nw=1&o1=3&op1=200,16711680&o2=3&op2=50,255&o3=1&cf=(ebit5yGrowth%3Erev5y)>

Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Read full article here »